Burden of Infection in Patients With and Without Secondary Immunodeficiency Disease Following Diagnosis of a Mature B Cell Malignancy
Patients with mature B cell malignancies such as chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), multiple myeloma (MM), and non-Hodgkin's lymphoma (NHL) are at risk of developing secondary immunodeficiency disease (SID) owing to the underlying disease process and the use of anti-cancer treatments with immunosuppressive effects.1 Patients with mature B cell malignancies and SID are susceptible to severe, recurrent, or persistent infections that result in substantial morbidity and increased mortality, as well as a considerable economic burden. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 9, 2024 Category: Hematology Authors: Joshua Richter, Matthew S. Davids, Colin Anderson-Smits, Marta Kamieniak, Kaili Ren, Michael Hull, Jasjit K. Multani, Drishti Shah, Csaba Siffel Source Type: research
Update on FDG-PET in pediatric lymphoma
Q J Nucl Med Mol Imaging. 2024 Mar;68(1):58-69. doi: 10.23736/S1824-4785.24.03560-X.ABSTRACTLymphoma represent the third most common malignant disease in childhood and adolescence. They are divided into pediatric Hodgkin lymphoma (P-HL) and pediatric non-Hodgkin lymphoma (P-NHL). In P-HL, excellent cure rates are achieved through combined modality treatment using chemotherapy and radiotherapy. For more than 20 years, FDG-PET has been an integral part of the treatment and guides its intensity through improved staging and precise assessment of chemotherapy response. In P-NHL, good cure rates are achieved with chemotherapy al...
Source: Molecular Medicine - April 8, 2024 Category: Molecular Biology Authors: Lars Kurch Regine Kluge Source Type: research
Update on FDG-PET in pediatric lymphoma
Q J Nucl Med Mol Imaging. 2024 Mar;68(1):58-69. doi: 10.23736/S1824-4785.24.03560-X.ABSTRACTLymphoma represent the third most common malignant disease in childhood and adolescence. They are divided into pediatric Hodgkin lymphoma (P-HL) and pediatric non-Hodgkin lymphoma (P-NHL). In P-HL, excellent cure rates are achieved through combined modality treatment using chemotherapy and radiotherapy. For more than 20 years, FDG-PET has been an integral part of the treatment and guides its intensity through improved staging and precise assessment of chemotherapy response. In P-NHL, good cure rates are achieved with chemotherapy al...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - April 8, 2024 Category: Nuclear Medicine Authors: Lars Kurch Regine Kluge Source Type: research
Optimized BEAC conditioning regimen improves clinical outcomes of autologous hematopoietic stem cell transplantation in non-Hodgkin lymphomas
Int J Hematol. 2024 Apr 8. doi: 10.1007/s12185-024-03755-7. Online ahead of print.ABSTRACTThe conditioning regimen is an important part of autologous hematopoietic stem cell transplantation (ASCT). We explored the efficacy and safety of an optimized BEAC (adjusted-dose, intermediate-dose cytarabine and reduced-dose cyclophosphamide, AD-BEAC) conditioning regimen for non-Hodgkin lymphoma (NHL). A total of 141 NHL patients received AD-BEAC or a standard-dose BEAC (SD-BEAC) conditioning regimen from January 2007 to December 2017, and 104 patients were included in the study after 1:1 propensity matching. The 5-year overall sur...
Source: International Journal of Hematology - April 8, 2024 Category: Hematology Authors: Sha Zhou Jun Rao Xiangyu Ma Yunjing Zeng Xixi Xiang Jiali Li Hongyun Liu Shijia Lin Song Dong Fu Li Xi Zhang Li Gao Source Type: research
Update on FDG-PET in pediatric lymphoma
Q J Nucl Med Mol Imaging. 2024 Mar;68(1):58-69. doi: 10.23736/S1824-4785.24.03560-X.ABSTRACTLymphoma represent the third most common malignant disease in childhood and adolescence. They are divided into pediatric Hodgkin lymphoma (P-HL) and pediatric non-Hodgkin lymphoma (P-NHL). In P-HL, excellent cure rates are achieved through combined modality treatment using chemotherapy and radiotherapy. For more than 20 years, FDG-PET has been an integral part of the treatment and guides its intensity through improved staging and precise assessment of chemotherapy response. In P-NHL, good cure rates are achieved with chemotherapy al...
Source: Molecular Medicine - April 8, 2024 Category: Molecular Biology Authors: Lars Kurch Regine Kluge Source Type: research
Update on FDG-PET in pediatric lymphoma
Q J Nucl Med Mol Imaging. 2024 Mar;68(1):58-69. doi: 10.23736/S1824-4785.24.03560-X.ABSTRACTLymphoma represent the third most common malignant disease in childhood and adolescence. They are divided into pediatric Hodgkin lymphoma (P-HL) and pediatric non-Hodgkin lymphoma (P-NHL). In P-HL, excellent cure rates are achieved through combined modality treatment using chemotherapy and radiotherapy. For more than 20 years, FDG-PET has been an integral part of the treatment and guides its intensity through improved staging and precise assessment of chemotherapy response. In P-NHL, good cure rates are achieved with chemotherapy al...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - April 8, 2024 Category: Nuclear Medicine Authors: Lars Kurch Regine Kluge Source Type: research
Optimized BEAC conditioning regimen improves clinical outcomes of autologous hematopoietic stem cell transplantation in non-Hodgkin lymphomas
Int J Hematol. 2024 Apr 8. doi: 10.1007/s12185-024-03755-7. Online ahead of print.ABSTRACTThe conditioning regimen is an important part of autologous hematopoietic stem cell transplantation (ASCT). We explored the efficacy and safety of an optimized BEAC (adjusted-dose, intermediate-dose cytarabine and reduced-dose cyclophosphamide, AD-BEAC) conditioning regimen for non-Hodgkin lymphoma (NHL). A total of 141 NHL patients received AD-BEAC or a standard-dose BEAC (SD-BEAC) conditioning regimen from January 2007 to December 2017, and 104 patients were included in the study after 1:1 propensity matching. The 5-year overall sur...
Source: International Journal of Hematology - April 8, 2024 Category: Hematology Authors: Sha Zhou Jun Rao Xiangyu Ma Yunjing Zeng Xixi Xiang Jiali Li Hongyun Liu Shijia Lin Song Dong Fu Li Xi Zhang Li Gao Source Type: research
Update on FDG-PET in pediatric lymphoma
Q J Nucl Med Mol Imaging. 2024 Mar;68(1):58-69. doi: 10.23736/S1824-4785.24.03560-X.ABSTRACTLymphoma represent the third most common malignant disease in childhood and adolescence. They are divided into pediatric Hodgkin lymphoma (P-HL) and pediatric non-Hodgkin lymphoma (P-NHL). In P-HL, excellent cure rates are achieved through combined modality treatment using chemotherapy and radiotherapy. For more than 20 years, FDG-PET has been an integral part of the treatment and guides its intensity through improved staging and precise assessment of chemotherapy response. In P-NHL, good cure rates are achieved with chemotherapy al...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - April 8, 2024 Category: Nuclear Medicine Authors: Lars Kurch Regine Kluge Source Type: research
Safety and Toxicity Profiles of CAR T Cell Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis
CONCLUSIONS: Overall, this study serves as the first to delineate toxicity profiles associated with various available CAR T products. By better understanding associated toxicities, it may become possible to tailor therapies towards individual patients and anticipate the development of toxicities at earlier stages.PMID:38582666 | DOI:10.1016/j.clml.2024.02.007 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 6, 2024 Category: Cancer & Oncology Authors: Samuel Yamshon Caitlin Gribbin Mohammad Alhomoud Nora Chokr Zhengming Chen Michelle Demetres Michelle Pasciolla John Leonard Tsiporah Shore Peter Martin Source Type: research
Safety and Toxicity Profiles of CAR T Cell Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis
CONCLUSIONS: Overall, this study serves as the first to delineate toxicity profiles associated with various available CAR T products. By better understanding associated toxicities, it may become possible to tailor therapies towards individual patients and anticipate the development of toxicities at earlier stages.PMID:38582666 | DOI:10.1016/j.clml.2024.02.007 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 6, 2024 Category: Cancer & Oncology Authors: Samuel Yamshon Caitlin Gribbin Mohammad Alhomoud Nora Chokr Zhengming Chen Michelle Demetres Michelle Pasciolla John Leonard Tsiporah Shore Peter Martin Source Type: research
Safety and Toxicity Profiles of CAR T Cell Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis
CONCLUSIONS: Overall, this study serves as the first to delineate toxicity profiles associated with various available CAR T products. By better understanding associated toxicities, it may become possible to tailor therapies towards individual patients and anticipate the development of toxicities at earlier stages.PMID:38582666 | DOI:10.1016/j.clml.2024.02.007 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 6, 2024 Category: Cancer & Oncology Authors: Samuel Yamshon Caitlin Gribbin Mohammad Alhomoud Nora Chokr Zhengming Chen Michelle Demetres Michelle Pasciolla John Leonard Tsiporah Shore Peter Martin Source Type: research
